Patents by Inventor David Hardick

David Hardick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Vasopressin receptor antagonists and products and methods related thereto
    Patent number: 11858943
    Abstract: Compounds are provided that antagonize vasopressin receptors, particularly the V1a receptor products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof: wherein A, B, G, R1, R1b, R1c, R2 and X are as defined herein.
    Type: Grant
    Filed: October 13, 2021
    Date of Patent: January 2, 2024
    Assignee: NEUMORA THERAPEUTICS, INC.
    Inventors: Robert M. Jones, Mariangela Urbano, Gary Brandt, David Hardick, Chris Knight, Jason Tierney
  • VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO
    Publication number: 20230093235
    Abstract: Compounds are provided that antagonize vasopressin receptors, particularly the V1a receptor products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof: wherein A, B, G, R1, R1b, R1c, R2 and X are as defined herein.
    Type: Application
    Filed: October 13, 2021
    Publication date: March 23, 2023
    Inventors: Robert M. Jones, Mariangela Urbano, Gary Brandt, David Hardick, Chris Knight, Jason Tierney
  • Radiolabeled compounds
    Patent number: 11541132
    Abstract: The present invention relates to radiolabeled compounds of formula I wherein either A, B, R1, R2, is labeled with a radionuclide selected from 3H, 11C and 18F and its use for imaging alpha synuclein and/or Abeta deposits in mammals.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: January 3, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Edilio Borroni, Luca Gobbi, Michael Honer, Martin Edelmann, Dale Mitchell, David Hardick, Wolfgang Schmidt, Christopher Steele, Mushtaq Mulla
  • Vasopressin receptor antagonists and products and methods related thereto
    Patent number: 11186577
    Abstract: Compounds are provided that antagonize vasopressin receptors, particularly the V1a receptor products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof: wherein A, B, G, R1, R1b, R1c, R2 and X are as defined herein.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: November 30, 2021
    Assignee: BLACKTHORN THERAPEUTICS, INC.
    Inventors: Robert M. Jones, Mariangela Urbano, Gary Brandt, David Hardick, Chris Knight, Jason Tierney
  • VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO
    Publication number: 20210317126
    Abstract: Compounds are provided that antagonize vasopressin receptors, particularly the V1a receptor products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof: wherein Q1, Q2, Q3, R2a, R2b, R3 and X are as defined herein.
    Type: Application
    Filed: March 5, 2021
    Publication date: October 14, 2021
    Inventors: Robert M. Jones, Mariangela Urbano, Gary Brandt, Mark Chambers, David Hardick, Chris Knight, Jason Tierney, Chris Lock
  • RADIOLABELED COMPOUNDS
    Publication number: 20200316232
    Abstract: The present invention relates to radiolabeled compounds of formula I wherein either A, B, R1, R2, is labeled with a radionuclide selected from 3H, C and 18F and its use for imaging alpha synuclein and/or Abeta deposits in mammals.
    Type: Application
    Filed: June 19, 2020
    Publication date: October 8, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Edilio BORRONI, Luca GOBBI, Michael HONER, Martin EDELMANN, Dale MITCHELL, David HARDICK, Wolfgang SCHMIDT, Christopher STEELE, Mushtaq MULLA
  • Vasopressin receptor antagonists and products and methods related thereto
    Patent number: 10538530
    Abstract: Compounds are provided that antagonize vasopressin receptors, particularly the V1a receptor products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof: wherein Q1, Q2, Q3, R2a, R2b, R3 and X are as defined herein.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: January 21, 2020
    Assignee: BlackThorn Therapeutics, Inc.
    Inventors: Robert M. Jones, Mariangela Urbano, Gary Brandt, Mark Chambers, David Hardick, Chris Knight, Jason Tierney, Chris Lock
  • VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO
    Publication number: 20190169202
    Abstract: Compounds are provided that antagonize vasopressin receptors, particularly the V1a receptor products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof: wherein Q1, Q2, Q3, R2a, R2b, R3 and X are as defined herein.
    Type: Application
    Filed: September 5, 2018
    Publication date: June 6, 2019
    Inventors: Robert M. Jones, Mariangela Urbano, Gary Brandt, Mark Chambers, David Hardick, Chris Knight, Jason Tierney, Chris Lock
  • VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO
    Publication number: 20190048013
    Abstract: Compounds are provided that antagonize vasopressin receptors, particularly the V1a receptor products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof: wherein A, B, G, R1, R1b, R1c, R2 and X are as defined herein.
    Type: Application
    Filed: June 5, 2018
    Publication date: February 14, 2019
    Inventors: Robert M. Jones, Mariangela Urbano, Gary Brandt, David Hardick, Chris Knight, Jason Tierney
  • Fused triazole derivatives as gamma secretase modulators
    Patent number: 9527853
    Abstract: The present invention provides fused bicyclic triazole derivatives of Formula (I) useful as gamma secretase modulators (GSM), for the treatment of Alzheimer's disease and related diseases.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: December 27, 2016
    Assignee: Ares Trading S.A.
    Inventors: Ben Whittaker, Chris Steele, David Hardick, Dale Mitchell, Vincent Pomel, Anna Quattropani, Dirk Beher
  • FUSED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS
    Publication number: 20150183790
    Abstract: The present invention provides fused bicyclic triazole derivatives of Formula (I) useful as gamma secretase modulators (GSM), for the treatment of Alzheimer's disease and related diseases.
    Type: Application
    Filed: June 14, 2013
    Publication date: July 2, 2015
    Applicant: Merck Patent GmbH
    Inventors: Ben Whittaker, Chris Steele, David Hardick, Dale Mitchell, Vincent Pomel, Anna Quattropani, Dirk Beher
  • Anti-malarial agents
    Patent number: 9024033
    Abstract: The present invention is related to a use of aminopyridine derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to aminopyridine derivatives useful for the preparation of a pharmaceutical foimulation for the inhibition of malaria parasite proliferation.
    Type: Grant
    Filed: January 17, 2011
    Date of Patent: May 5, 2015
    Assignee: MMV Medicines for Malaria Venture
    Inventors: Michael John Witty, David Hardick
  • NEW ANTI-MALARIAL AGENTS
    Publication number: 20120295905
    Abstract: The present invention is related to a use of aminopyridine derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to aminopyridine derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation.
    Type: Application
    Filed: January 17, 2011
    Publication date: November 22, 2012
    Applicant: MMV MEDICINES FOR MALARIA VENTURE
    Inventors: Michael John Witty, David Hardick